author keywords: ACE-inhibitor; enalapril; genotype; pharmacogenetic; pharmacogenomic

MeSH headings : Angiotensin-Converting Enzyme Inhibitors / pharmacology; Animals; Dog Diseases / genetics; Dog Diseases / metabolism; Dogs; Genetic Predisposition to Disease; Genotype; Humans; Mitral Valve Prolapse / enzymology; Mitral Valve Prolapse / genetics; Peptidyl-Dipeptidase A / genetics; Peptidyl-Dipeptidase A / metabolism; Polymorphism, Genetic; Renin-Angiotensin System / physiology; Retrospective Studies

TL;DR: The results support the use of aldosterone receptor antagonists with ACE‐inhibitors when RAAS inhibition is indicated for dogs, especially those positive for the ACE gene polymorphism, which did not alter baseline RAAS activity. (via Semantic Scholar)